HELP
CYBIN INC.
$4.15
-6.32%
$207.6M
No data for this timeframe.
Vol
Market Cap$207.6M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders2 funds
Inst. Value$10.7M
Inst. Activity1 buys / 1 sells
Reddit Sentiment70° Bullish
SEC Reports6
Press Releases4
Recent Activity
Jun 1, 2026
SEC
Helus Pharma (Cybin Inc.) announced its interim CEO will participate in a fireside chat at the Jefferies Global Healthca
6-K — Impact 2/10
Apr 30, 2026
SEC
Helus Pharma (Cybin Inc.) filed a 6-K announcing that Interim CEO Eric So will speak on a panel at the Milken Institute
6-K — Impact 2/10
Apr 28, 2026
SEC
Helus Pharma (Cybin Inc.) announced a collaboration with TARA Mind to support recruitment for its HLP003 Phase 3 MDD tri
6-K — Impact 3/10
Inst.
MORGAN STANLEY — DOUBLED
1,299,756 shares ($10.6M)
Inst.
BANK OF AMERICA CORP — NEAR_EXIT
4,248 shares ($34.7K)
Apr 30, 2026
Press
Helus Pharma announced a collaboration with TARA Mind to support recruitment for its Phase 3 HLP003 program in major dep
Impact 3/10
Apr 30, 2026
contract
CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
<p align="justify">NEW YORK & TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- In a release issued
Apr 20, 2026
Press
Helus Pharma welcomed a White House Executive Order aimed at accelerating research, regulatory pathways, and patient acc
Impact 4/10
Price Targets
$43.18
+940.5% upside
Strong Buy
Current $4.15
Low $7.93
Median $45.27
High $92.85
8 analysts
$7.93
$92.85
Analyst Ratings
3Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 13, 2026 | TD Cowen | INITIATE | Buy |
| Mar 2, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.13 ▼ -43.4% | $-1.47 — $-0.86 | 22% YoY | 5 |
| Next Q | $-1.14 ▼ -8.9% | $-1.55 — $-0.92 | -18% YoY | 4 |
| Current FY | $-5.24 ▼ -22.2% | $-5.75 — $-4.90 | 6% YoY | 5 |
| Next FY | $-4.40 ▼ -9.1% | $-5.55 — $-3.63 | 16% YoY | 4 |
Latest Reports
NEUTRAL
6-K
2/10
Helus Pharma (Cybin Inc.) announced its interim CEO will participate in a fireside chat at the Jefferies Global Healthca
Jun 1, 2026
NEUTRAL
Press
3/10
Helus Pharma announced a collaboration with TARA Mind to support recruitment for its Phase 3 HLP003 program in major dep
Apr 30, 2026
NEUTRAL
6-K
2/10
Helus Pharma (Cybin Inc.) filed a 6-K announcing that Interim CEO Eric So will speak on a panel at the Milken Institute
Apr 30, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $10.6M | DOUBLED |
| BANK OF AMERICA CORP | $34.7K | NEAR_EXIT |
Reddit Sentiment
70°
Bullish
Bearish
Neutral
Bullish
2 institutional holders with $10.7M total value (1,304,004 shares) as of 2025-Q4. Top holders: MORGAN, BANK.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 1,299,756 | $10.6M | 99.7% | DOUBLED +470.9% |
| 2 | BANK OF AMERICA CORP /DE/ | 4,248 | $34.7K | 0.3% | NEAR_EXIT -93.3% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | DOUBLED | 227,661 | 1,299,756 | +470.9% | $10.6M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 63,056 | 4,248 | -93.3% | $34.7K | 2025-Q4 |
| UBS Group AG | ADD | 179,443 | 303,740 | +69.3% | $1.8M | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 22,821 | 227,661 | +897.6% | $1.3M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 29,443 | 63,056 | +114.2% | $371.4K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 17,653 | 29,443 | +66.8% | $247.0K | 2025-Q2 |
| MORGAN STANLEY | TRIM | 46,526 | 22,821 | -51.0% | $191.5K | 2025-Q2 |
| UBS Group AG | DOUBLED | 1,751 | 177,592 | +10042.3% | $1.1M | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 193,800 | 122,402 | -36.8% | $776.0K | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 10,642 | 46,526 | +337.2% | $295.0K | 2025-Q1 |
| CITADEL ADVISORS LLC | NEW | — | 193,800 | — | $1.7M | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 2,809 | 10,642 | +278.9% | $93.9K | 2024-Q4 |
| UBS Group AG | NEAR_EXIT | 10,523 | 1,751 | -83.4% | $15.4K | 2024-Q4 |
| MORGAN STANLEY | NEAR_EXIT | 106,404 | 2,809 | -97.4% | $25.0K | 2024-Q3 |
| MORGAN STANLEY | EXIT | 106,404 | 0 | -100.0% | $0.00 | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
6 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 6 neutral. Avg impact: 2.8/10.
NEUTRAL
6-K
2/10
Helus Pharma (Cybin Inc.) announced its interim CEO will participate in a fireside chat at the Jeffe
Jun 1, 2026
NEUTRAL
6-K
2/10
Helus Pharma (Cybin Inc.) filed a 6-K announcing that Interim CEO Eric So will speak on a panel at t
Apr 30, 2026
NEUTRAL
6-K
3/10
Helus Pharma (Cybin Inc.) announced a collaboration with TARA Mind to support recruitment for its HL
Apr 28, 2026
NEUTRAL
6-K
3/10
Cybin Inc. (HELP) issued a press release through its commercial entity Helus Pharma welcoming a Whit
Apr 20, 2026
NEUTRAL
6-K
4/10
Cybin Inc. (HELP) announced the immediate departure of CEO Michael Cola and the appointment of co-fo
Apr 20, 2026
NEUTRAL
6-K
3/10
Cybin Inc. (HELP) announced the appointment of Dr. Ken Kramer as Senior Vice President, Medical Affa
Apr 16, 2026
NEUTRAL
3/10
Helus Pharma announced a collaboration with TARA Mind to support recruitment for its Phase 3 HLP003
Apr 30, 2026
NEUTRAL
4/10
Helus Pharma welcomed a White House Executive Order aimed at accelerating research, regulatory pathw
Apr 20, 2026
NEUTRAL
3/10
Helus Pharma announced the appointment of Dr. Ken Kramer as Senior Vice President, Medical Affairs,
Apr 16, 2026
BULLISH
8/10
Helus Pharma announced positive topline results from a Phase 2 signal detection study of HLP004, an
Mar 5, 2026
Current analyst consensus: Strong Buy (88% buy). Based on 8 analysts: 3 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$43.18 mean target
+940.5% upside
Strong Buy (3.00)
$7.93 Low
$92.85 High
| Metric | Value |
|---|---|
| Current Price | $4.15 |
| Target Low | $7.93 |
| Target Mean | $43.18 |
| Target Median | $45.27 |
| Target High | $92.85 |
| # Analysts | 8 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-03-31 |
$-1.13 | $-1.47 | $-0.86 | 22.4% | -43.4% | 1↑ 2↓ | $0.0B | 0.0% | 5 |
| Next Q 2026-06-30 |
$-1.14 | $-1.55 | $-0.92 | -17.9% | -8.9% | 1↑ 2↓ | $0.0B | 0.0% | 4 |
| Current FY 2026-03-31 |
$-5.24 | $-5.75 | $-4.90 | 6.3% | -22.2% | 0↑ 2↓ | $0.0B | 0.0% | 5 |
| Next FY 2027-03-31 |
$-4.40 | $-5.55 | $-3.63 | 16.0% | -9.1% | 1↑ 2↓ | $0.0B | 0.0% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.133 | |
| 7d ago | $-0.969 | -0.164 |
| 30d ago | $-0.790 | -0.343 |
| 60d ago | $-0.790 | -0.343 |
| 90d ago | $-0.790 | -0.343 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 13, 2026 | TD Cowen | INITIATE | — | Buy |
| Mar 2, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
70°
Bullish
Bearish
Neutral
Bullish
29 mentions
18 bullish
5 bearish
28 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 1, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Jun 1, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 2, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 2, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 24, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 24, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 23, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 31, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Mar 31, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Mar 29, 2026 | 2 | 33° Cool | 0 | 2 | 2 |
| Mar 29, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 27, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 27, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 18, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 18, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 14, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 13, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Mar 13, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Mar 11, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 6, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 6, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 3, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 3, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 3, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Mar 3, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Mar 1, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 27, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 1, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Worst Analyst Alive. Pump and dump Schemes
▲ 1
💬 0
⚡ 0.5
18M, want my 20,000 (INR) to work. HELP!
▲ 1
💬 0
⚡ 0.5
NEW TRADING TOOL: HELP NEEDED
▲ 1
💬 1
⚡ 0.5
YOU CAN REACH OUT TO GREAT WHIP RECOVERY CYBER SERVICES FOR HELP TO RECOVER YOUR STOLEN BTC OR ETH BACK
▲ 1
💬 1
⚡ 0.5
New trader/investor NEED HELP
▲ 1
💬 0
⚡ 0.5
Don’t invest in Microcaps
▲ 1
💬 0
⚡ 0.5
HELP : Moomoo app 24hr Stop Loss
▲ 1
💬 1
⚡ 0.5
HELP! Robinhood Gold Roth IRA
▲ 1
💬 0
⚡ 0.5
Time to buy VIAV
▲ 1
💬 2
⚡ 0.5
HELP : Moomoo app 24hr Stop Loss
▲ 1
💬 0
⚡ 0.5
ALOY- HELP WITH DD
▲ 1
💬 0
⚡ 0.5
HELP W stocks
▲ 1
💬 0
⚡ 0.5
TSMC STRATEGY - NEED HELP!!
▲ 1
💬 0
⚡ 0.5
I NEED YOUR HELP
▲ 1
💬 0
⚡ 0.0
NEED HELP!
▲ 1
💬 0
⚡ 0.0
Apr 30, 2026
contract
CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
<p align="justify">NEW YORK & TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline on April 28, 2026, by Helu
Apr 30, 2026
other
Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference
<p align="justify">NEW YORK and TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceu
Apr 28, 2026
contract
Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
<p align="justify">NEW YORK & TORONTO, April 28, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmac
Apr 23, 2026
other
Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan
<p align="justify">NEW YORK and TORONTO, April 23, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceu
Apr 20, 2026
fda
Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions
<p align="justify">NEW YORK and TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceu
Apr 16, 2026
leadership
Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs
<p align="justify">NEW YORK and TORONTO, April 16, 2026 (GLOBE NEWSWIRE) -- Helus Pharma<sup>TM</sup> (Nasdaq: HELP) (Cboe CA: HELP), a clinical sta
Mar 12, 2026
other
Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer
<p align="justify">NEW YORK and TORONTO, March 12, 2026 (GLOBE NEWSWIRE) -- Helus Pharma<sup>TM</sup> (Nasdaq: HELP) (Cboe CA: HELP), a clinical sta
Mar 6, 2026
short_interest
FTD: HELP — 255,244 shares ($1.4M) failed to deliver
Settlement: 20260306, Price: $5.64, FTD Value: $1,439,576.16, CYBIN INC COM NEW (CANADA)
Mar 5, 2026
fda
Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder
<p><strong>Figure 1</strong></p>